Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis

Naturally occurring phenolic compounds have been shown to sensitize prostate cancer cells to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. TRAIL is a potent stimulator of apoptosis in cancer cells and an important immune effector molecule in the surveillance and prostate cancer cells were treated with TRAIL and artepillin C. staining by flow cytometry and fluorescence microscopy. Death receptor (DR) (TRAIL-R1/DR4 and TRAIL-R2/DR5) membrane potential (Delta Psi m) was evaluated using DePsipher NF-kappa B (p65) activation was confirmed with the ELISA-based TransAM NF-kappa B kit. Caspase-8 and caspase-3 activities were that artepillin C sensitized the TRAIL-resistant LNCaP cells the expression of TRAIL-R2 and decreased the activity of NF-kappa B. Co-treatment with TRAIL and artepillin C induced the disruption of At Pm. These findings show that Prostate cancer elimination of developing tumours. However, many cancer cells are resistant to TRAIL-mediated death. In this study, we aimed to determine the mechanisms by which TRAIL resistance can be overcome in prostate cancer cells by 3,5-dipreny1-4-hydroxycinnamic acid (artepillin C). Artepillin C is a bioactive component of Brazilian green propolis that possesses antitumour and chemopreventive activities. TRAIL-resistant LNCaP Cytotoxicity was measured by MTT and lactate dehydrogenase (LDH) assays. Apoptosis was detected using Annexin V-FITC expression was analyzed using flow cytometry. Mitochondrial staining by fluorescence microscopy. The inhibition of determined by colorimetric protease assays. The results showed by engaging the extrinsic (receptor-mediated) and intrinsic (mitochondrial) apoptotic pathways. Artepillin C increased significant activation of caspase-8 and caspase-3, as well as the cells can be sensitized to TRAIL-mediated immunoprevention by artepillin C and confirm the role of phenolic compounds in prostate cancer immunochemoprevention.